Clinical Trial Update: A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab) [Phase 4]

View source ↗

Summary

Phase 4 study evaluating reduced dosing frequency of tocilizumab (RoActemra/Actemra) in pediatric patients with systemic juvenile idiopathic arthritis experienc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis
• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• Actemra (tocilizumab)
• RoActemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Juvenile Idiopathic Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2020-04-24